FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

FDA Pauses Release of Complete Response Letters as it Mulls Policy

FDA temporarily suspends its controversial practice of publicly releasing Complete Response Letters for rejected drug applications while it evaluates ...

latest-news-card-1
Medical Devices

J&J Wins Approval for Dual-Energy Cardiac Ablation Platform

FDA approves Johnson & Johnsons Dual Energy Thermocool Smarttouch SF Platform, a catheter ablation system that combines pulsed field and radiofrequenc...

latest-news-card-1
Human Drugs

LyfeUnit Selling Unapproved Ketamine Products: FDA

FDA warns that the LyfeUnit Web site is selling unapproved adulterated and misbranded ketamine products.

latest-news-card-1
Federal Register

FDA Moves to Cement Complete Response Letter Transparency Policy

FDA looks to formalize one of its most significant transparency initiatives in decades: the public release of Complete Response Letters issued to comp...

latest-news-card-1

Companies Can Use AI to Prepare for Inspections

Former FDAer David Elder recommends that companies qualify AI tools to assist them in preparing for and responding to FDA inspections.

latest-news-card-1
Human Drugs

QuVa Pharma Inspection Observations

FDA releases the form FDA-483 with three observations from an inspection at the QuVa Pharma outsourcing facility in Sugar Land, TX.

latest-news-card-1
Human Drugs

Vera Therapeutics' Trutakna Approved for IgA Nephropathy

FDA grants Vera Therapeutics an accelerated approval for Trutakna (atacicept-vymj) to reduce proteinuria in adults with primary immunoglobulin A nephr...

latest-news-card-1
Marketing

FDA Cites Lundbeck Over Vyepti Promotional Claims

FDA sends Lundbeck Seattle Biopharmaceuticals an untitled letter alleging that promotional materials for its migraine therapy Vyepti (eptinezumab-jjmr...

latest-news-card-1
Human Drugs

Saol Therapeutics Resubmits Rare Disease Therapy SL1009

Saol Therapeutics refiles its NDA for SL1009 (sodium dichloroacetate), an investigational treatment for pyruvate dehydrogenase complex deficiency, a r...

Medical Devices

MDUFA Performance Goals, Procedures for 2028-2032

FDA releases the draft MDUFA performance goals and procedures approved by CDRH and CBER for the 2027 renewal of MDUFA that will cover FY 2028-2032.